IDEAYA Biosciences/$IDYA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About IDEAYA Biosciences
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
- Ticker
- $IDYA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 145
- Headquarters
- South San Francisco, United States
- Website
- www.ideayabio.com
IDYA Metrics
BasicAdvanced
$3.1B
-
-$1.96
-0.08
-
Price and volume
Market cap
$3.1B
Beta
-0.08
52-week high
$42.68
52-week low
$26.81
Average daily volume
901K
Financial strength
Current ratio
10.451
Quick ratio
10.213
Long term debt to equity
0.023
Total debt to equity
0.024
Profitability
EBITDA (TTM)
-214.195
Gross margin (TTM)
-59.75%
Net profit margin (TTM)
-74.75%
Operating margin (TTM)
-92.66%
Revenue per employee (TTM)
$1,610,000
Management effectiveness
Return on assets (TTM)
-11.54%
Return on equity (TTM)
-16.22%
Valuation
Price to revenue (TTM)
12.214
Price to book
2.57
Price to tangible book (TTM)
2.57
Price to free cash flow (TTM)
-25.112
Free cash flow yield (TTM)
-3.98%
Free cash flow per share (TTM)
-1.273
Growth
Revenue change (TTM)
3,244.67%
Earnings per share change (TTM)
-48.35%
3-year revenue growth (CAGR)
73.09%
3-year earnings per share growth (CAGR)
8.41%
What the Analysts think about IDYA
Analyst ratings (Buy, Hold, Sell) for IDEAYA Biosciences stock.
Analyst projections of the future price of IDEAYA Biosciences stock.
Bulls say / Bears say
In the randomised OptimUM-02 trial, darovasertib plus crizotinib extended median progression-free survival to 6.9 months versus 3.1 months with investigator’s choice, and response rates were 37.1% versus 5.8%. This gives IDEAYA a strong clinical and regulatory opportunity in HLA-A*02:01-negative metastatic uveal melanoma. (Journal of Clinical Oncology)
Results from small, single-arm HLA-A*02:01-positive cohorts suggest activity both before treatment and after tebentafusp, potentially extending darovasertib’s reach beyond the population studied in OptimUM-02. In the treatment-naïve group of 13 patients, median progression-free survival was 7.4 months; in 15 patients previously treated with tebentafusp, it was 5.7 months. (IDEAYA Biosciences)
IDEAYA reported $1.24 billion in cash and marketable securities at the end of June and said its cash runway extends into 2030 on its current plan. That gives it scope to advance several programmes without relying on near-term financing. (IDEAYA Biosciences)
OptimUM-02’s overall-survival data were still immature, and the next planned interim analysis is expected in mid-2027. The PFS result supports a potential accelerated approval, but the survival benefit and full-approval case remain unresolved. (IDEAYA Biosciences)
The combination produced grade 3 or 4 treatment-related adverse events in 40.6% of patients, including diarrhoea in 10.0% and syncope in 7.1%. These side effects could make treatment harder for some patients to tolerate, even though the rate of severe events was similar to the control arm. (IDEAYA Biosciences)
The June financing added 7.2 million shares and warrants for a further 5.6 million shares, while the second-quarter net loss was $112.5 million. The large cash balance therefore came with shareholder dilution, and ongoing development spending remains substantial. (IDEAYA Biosciences)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
IDYA Financial Performance
Revenues and expenses
IDYA Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing IDYA
Fund name | Fund size | $IDYA weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.28% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.28% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.28% |
iShares Ageing Population$AGED | $953M | 0.25% |
iShares Ageing Population€AGED | $903M | 0.25% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.